Litcius/Paper detail

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial

Chantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S. Bajaj, Wendy Lane, Ana Laura de Souza Almeida Matos, Sreenivasa Murthy, Karolina Stachlewska, Julio Rosenstock

2023The Lancet135 citationsDOI

Topics & Concepts

MedicineInsulin glargineInsulinBasal insulinDiabetes mellitusType 2 diabetesOpen labelBolus (digestion)Internal medicineType 1 diabetesInsulin degludecEndocrinologyPediatricsRandomized controlled trialDiabetes Management and ResearchDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patients
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial | Litcius